50 related articles for article (PubMed ID: 24917443)
1. Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study.
Bares M; Novak T; Kopecek M; Stopkova P; Höschl C
Int J Psychiatry Clin Pract; 2010 Nov; 14(4):303-8. PubMed ID: 24917443
[TBL] [Abstract][Full Text] [Related]
2. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study.
Bares M; Novak T; Kopecek M; Stopkova P; Sos P
Neuro Endocrinol Lett; 2009; 30(6):723-8. PubMed ID: 20038931
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study.
Bares M; Novak T; Kopecek M; Stopkova P; Cermak J; Kozeny J; Höschl C
Int J Psychiatry Clin Pract; 2013 Feb; 17(1):35-43. PubMed ID: 22486580
[TBL] [Abstract][Full Text] [Related]
4. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
Malhi GS; Ng F; Berk M
Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
[TBL] [Abstract][Full Text] [Related]
5. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
[TBL] [Abstract][Full Text] [Related]
6. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
8. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.
Nakajima S; Uchida H; Suzuki T; Watanabe K; Hirano J; Yagihashi T; Takeuchi H; Abe T; Kashima H; Mimura M
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1983-9. PubMed ID: 21889560
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
10. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study.
Bares M; Brunovsky M; Kopecek M; Stopkova P; Novak T; Kozeny J; Höschl C
J Psychiatr Res; 2007; 41(3-4):319-25. PubMed ID: 16889798
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine for treatment-resistant unipolar depression.
Nierenberg AA; Feighner JP; Rudolph R; Cole JO; Sullivan J
J Clin Psychopharmacol; 1994 Dec; 14(6):419-23. PubMed ID: 7884023
[TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
13. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
[TBL] [Abstract][Full Text] [Related]
14. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.
Gabriel A
Depress Anxiety; 2006; 23(8):485-8. PubMed ID: 16845646
[TBL] [Abstract][Full Text] [Related]
15. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
16. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
17. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
18. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.
Thase ME; Montgomery S; Papakostas GI; Bauer M; Trivedi MH; Svedsäter H; Locklear JC; Gustafsson U; Datto C; Eriksson H
Int Clin Psychopharmacol; 2013 May; 28(3):113-20. PubMed ID: 23485955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
